Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid-induced osteoporosis.

R Kumar1

  • 1Divisions of Nephrology, Endocrinology and Metabolism, Department of Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA. rkumar@mayo.edu

Current Opinion in Nephrology and Hypertension
|August 10, 2001
PubMed
Summary

Glucocorticoid-induced osteoporosis is a common issue, especially in transplant and rheumatology patients. Early intervention with new therapies like bisphosphonates and parathyroid hormone can effectively treat bone loss.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The expression of milligram amounts of functional human 1,25-dihydroxyvitamin D3 receptor in a bacterial expression system.

Biochemical and biophysical research communications·1992
Same author

Plasma cell granuloma of the lung.

Indian pediatrics·1992
Same author

Gastrin-dependent inhibitory effects of octreotide on the genesis of gastric ECLomas.

Surgery·1992
Same author

MR imaging of clival and paraclival lesions.

AJR. American journal of roentgenology·1992
Same author

Intestinal colonization & production of diarrhoea by enteroadherent-aggregative Escherichia coli.

The Indian journal of medical research·1992
Same author

Caffeine-derived N-nitroso compounds--I: Nitrosatable precursors from caffeine and their potential relevance in the etiology of oesophageal and gastric cancers in Kashmir, India.

Carcinogenesis·1992

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoid-induced osteoporosis (GIOP) is a prevalent complication in patients undergoing glucocorticoid therapy for conditions like transplantation, renal disease, and rheumatological disorders.
  • Inadequate evaluation and treatment of GIOP are frequent, despite early bone loss occurring with high-dose glucocorticoid administration.
  • Elderly patients with pre-existing low bone density are particularly susceptible to fractures due to glucocorticoid-associated bone disease.

Purpose of the Study:

  • To review the mechanisms underlying glucocorticoid-associated bone disease.
  • To highlight the significance of GIOP in specific patient populations.
  • To discuss emerging therapeutic strategies for managing GIOP.

Main Methods:

Related Experiment Videos

  • Literature review focusing on glucocorticoid-induced osteoporosis.
  • Analysis of current understanding of bone loss mechanisms.
  • Evaluation of novel therapeutic agents.

    • Main Results:

    • Bone loss commences early in high-dose glucocorticoid therapy.
    • Specific patient groups, including the elderly with low bone density, face heightened fracture risk.
    • New insights into the pathophysiology of GIOP are emerging.

    Conclusions:

    • Glucocorticoid-induced osteoporosis requires appropriate patient evaluation and management.
    • Emerging anti-resorptive (bisphosphonates) and anabolic (parathyroid hormone) agents show promise for effective GIOP treatment.